Clinical Trial Update: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of loncastuximab tesirine and mosunetuzumab for relapsed or refractory diffuse large B-cell lymphoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3b
• Indolent B-cell Non-hodgkin Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Chronic Lymphocytic Leukemia

Drugs mentioned

• LUNSUMIO (mosunetuzumab)
• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Status: RECRUITING